Related posts
Stocks sink for the day and weekMoody’s downgrade pressures stocksTSX and Dow gain for the weekThis summary was created by AI, based on 17 opinions in the last 12 months.
Zoetis Inc (ZTS-N) is a global leader in the animal health industry with a strong market position and a focus on both livestock and pet care. The company has a long history of around 65 years and was spun off from Pfizer 10 years ago. Despite a recent pullback, experts believe that the stock offers an attractive opportunity for long-term investors. Zoetis continues to invest in R&D, has a strong product pipeline, and demonstrates consistent revenue growth. With potential for growth in the pet care sector and a new pipeline of drugs, the company remains a strong investment option, albeit at a premium valuation.
Likes the industry in general. A leader. Vets like its products. Not a lot of generic competition. Diversified in types of care. Studies show that pet spending is resilient even during slowdowns. Attractive entry point.
Shares are declining because they now face competition. It's no longer a one-horse race.
A bit disappointing. Headwind from near-term, cyclical pressures as economy weakens and vet visits decline. Company sees itself as defensive -- people prioritize their pets, aging population, younger generation having pets instead of children. Competition on drugs, adverse press to dog pain management drug. Still likes longer, secular trend.
2/3 pet pharma, 1/3 livestock. Time to market is lower than for human pharma, not as much generic competition. Overhang from negative press about unwanted effects from painkillers -- anecdotal, not based on data. Good growth going forward. Yield is 1%.
(Analysts’ price target is $206.40)Livestock has come back since Covid plus, as people become wealthier, they eat more protein. Pet side is going like gangbusters. Lots of products in pipeline. Incredible run during Covid, now taking a break. Will continue to do well.
Pet division is about 2/3 of revenue, livestock makes up the rest. Around for 65 years, spun off from PFE 10 years ago. Animal health industry has very little generic competition, so product life tends to be over 25 years. Leading share globally. Invests in R&D. Pullback is attractive opportunity. Yield is 1%.
(Analysts’ price target is $217.14)That conversion metric is a good one. Transitioning some drugs, so growth has slowed, impacting free cashflow. Increase in R&D taking up capital. New drugs in pipeline. Story still stands. Good value compounder over time.
Their last quarter was weak, but he thinks it's a one-off event. Be believes in the CEO and company long term.
Stock's done well, especially with recent rally. For new money, wait for pullback, and we'll get that eventually. Great products, especially launch of drug for canine arthritic pain. Pet division is somewhat recession-resistant.
It has two parts in animal healthcare: livestock and pet care and it is the second part which has done very well. The drugs component has advantages over regular pharma companies and there are great products in the pipelines. There are only two other big players and Zoetis is the biggest of the three.
Likes their growth. Spending on pets remains steady, a plus. But the PE is 35x, so no.
Zoetis Inc is a American stock, trading under the symbol ZTS-N on the New York Stock Exchange (ZTS). It is usually referred to as NYSE:ZTS or ZTS-N
In the last year, 12 stock analysts published opinions about ZTS-N. 9 analysts recommended to BUY the stock. 3 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Zoetis Inc.
Zoetis Inc was recommended as a Top Pick by on . Read the latest stock experts ratings for Zoetis Inc.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
12 stock analysts on Stockchase covered Zoetis Inc In the last year. It is a trending stock that is worth watching.
On 2024-10-11, Zoetis Inc (ZTS-N) stock closed at a price of $190.08.
Companion pets are a big thing. Growing need for protein from livestock. Above 200-day MA, but that's moving sideways. Trendlines are not fantastic. Trading at 31x, with 10% growth rate, PEG of 3, a bit expensive.